T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab
作者： Hannah Dzimitrowicz , Michael Berger , Craig Vargo , Annette Hood , Osama Abdelghany
关键词: Metastatic breast cancer 、 Taxane 、 Prior Therapy 、 Trastuzumab 、 Cancer 、 Retrospective cohort study 、 Internal medicine 、 Response Evaluation Criteria in Solid Tumors 、 Oncology 、 Pertuzumab 、 Medicine
摘要: PurposeAdo-trastuzumab emtansine (T-DM1) is currently approved for treatment in patients with human epidermal growth factor receptor 2 (HER2)–positive, metastatic breast cancer (MBC) who previously received trastuzumab and a taxane. However, there are no data on the activity of T-DM1 prior pertuzumab, which now included as standard first-line therapy. The goal this study was to assess efficacy routine clinical practice contemporary patient population that both pertuzumab.Patients MethodsWe identified all HER2-positive MBC after pertuzumab between March 1, 2013, July 15, 2015, via electronic pharmacy records departmental databases at three institutions: MD Anderson Cancer Center, Smilow Hospital Yale, James Ohio State University. We reviewed medical each case confirm sequencing outcome.ResultsOf p...
utsystem.edu参考文章(23)
Milena Sant, Claudia Allemani, Franco Berrino, Michel P. Coleman, Tiiu Aareleid, Gilles Chaplain, Jan Willem Coebergh, Marc Colonna, Paolo Crosignani, Arlette Danzon, Massimo Federico, Lorenzo Gafà, Pascale Grosclaude, Guy Hédelin, Josette Macè-Lesech, Carmen Martinez Garcia, Henrik Møller, Eugenio Paci, Nicole Raverdy, Brigitte Tretarre, Evelyn M. I. Williams, , Breast carcinoma survival in Europe and the United States Cancer. ,vol. 100, pp. 715- 722 ,(2004) , 10.1002/CNCR.20038
Denise A. Yardley, Peter A. Kaufman, Adam Brufsky, Marianne Ulcickas Yood, Hope Rugo, Musa Mayer, Cheng Quah, Bongin Yoo, Debu Tripathy, Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer Breast Cancer Research and Treatment. ,vol. 145, pp. 725- 734 ,(2014) , 10.1007/S10549-014-2916-8
Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger, Lisa M. Crocker, Kathryn L. Parsons, Elaine Mai, Walter A. Blättler, John M. Lambert, Ravi V.J. Chari, Robert J. Lutz, Wai Lee T. Wong, Frederic S. Jacobson, Hartmut Koeppen, Ralph H. Schwall, Sara R. Kenkare-Mitra, Susan D. Spencer, Mark X. Sliwkowski, Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate Cancer Research. ,vol. 68, pp. 9280- 9290 ,(2008) , 10.1158/0008-5472.CAN-08-1776
Gideon M. Blumenthal, Nancy S. Scher, Patricia Cortazar, Somesh Chattopadhyay, Shenghui Tang, Pengfei Song, Qi Liu, Kimberly Ringgold, Anne M. Pilaro, Amy Tilley, Kathryn E. King, Laurie Graham, Barbara L. Rellahan, Wendy C. Weinberg, Bo Chi, Colleen Thomas, Patricia Hughes, Amna Ibrahim, Robert Justice, Richard Pazdur, First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-positive Metastatic Breast Cancer Clinical Cancer Research. ,vol. 19, pp. 4911- 4916 ,(2013) , 10.1158/1078-0432.CCR-13-1212
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
Valentina Rossi, Franco Nolè, Stefania Redana, Laura Adamoli, Rossella Martinello, Gaetano Aurilio, Elena Verri, Anna Sapino, Giuseppe Viale, Massimo Aglietta, Filippo Montemurro, Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. The Breast. ,vol. 23, pp. 44- 49 ,(2014) , 10.1016/J.BREAST.2013.10.005
Ian E. Krop, Patricia LoRusso, Kathy D. Miller, Shanu Modi, Denise Yardley, Gladys Rodriguez, Ellie Guardino, Michael Lu, Maoxia Zheng, Sandhya Girish, Lukas Amler, Eric P. Winer, Hope S. Rugo, A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine Journal of Clinical Oncology. ,vol. 30, pp. 3234- 3241 ,(2012) , 10.1200/JCO.2011.40.5902
Ines Vaz-Luis, Davinia Seah, Erin M Olson, Nikhil Wagle, Otto Metzger-Filho, Jessica Sohl, Georgia Litsas, Harold J Burstein, Ian E Krop, Eric P Winer, Nancy U Lin, None, Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study Clinical Breast Cancer. ,vol. 13, pp. 254- 263 ,(2013) , 10.1016/J.CLBC.2013.02.010
Laleh Amiri-Kordestani, Gideon M. Blumenthal, Qiang Casey Xu, Lijun Zhang, Shenghui W. Tang, Linan Ha, Wendy C. Weinberg, Bo Chi, Reyes Candau-Chacon, Patricia Hughes, Anne M. Russell, Sarah Pope Miksinski, Xiao Hong Chen, W. David McGuinn, Todd Palmby, Sarah J. Schrieber, Qi Liu, Jian Wang, Pengfei Song, Nitin Mehrotra, Lisa Skarupa, Kathleen Clouse, Ali Al-Hakim, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur, Patricia Cortazar, FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer Clinical Cancer Research. ,vol. 20, pp. 4436- 4441 ,(2014) , 10.1158/1078-0432.CCR-14-0012
A. Schneeweiss, S. Chia, T. Hickish, V. Harvey, A. Eniu, R. Hegg, C. Tausch, J.H. Seo, Y.-F. Tsai, J. Ratnayake, V. McNally, G. Ross, J. Cortés, Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Annals of Oncology. ,vol. 24, pp. 2278- 2284 ,(2013) , 10.1093/ANNONC/MDT182